Julia A M, Canal P, Berg D, Bachaud J M, Daly N J, Bugat R
Groupe de Recherche, Centre Claudius Regaud, Toulouse, France.
Int J Radiat Oncol Biol Phys. 1991 Feb;20(2):347-50. doi: 10.1016/0360-3016(91)90118-n.
The efficiency, acute and delayed toxicities of different radio-chemotherapeutic combinations were assessed on an in vivo model (Krebs II ascitic carcinoma grafted to female Swiss mice). Mice were given whole abdomen irradiation (WAI) 2.5 to 10 Gy as a single dose (WAI). CDDP was given intraperitoneally at 0.5 to 4 mg/kg dose level, 12 hr before or after WAI. There was a relationship between dose of CDDP and increase of life span (ILS) of mice. However, WAI did not increase the life span. When a single dose of 2 mg/kg CDDP was given prior to a 2.5 Gy WAI, the ILS reached 47%. By contrast, it was only 37% when treatment sequence was reversed. When the WAI dose level was increased to 5 Gy, the ILS was not increased. The jejunal crypt cell number, determined 3 days after the last treatment, was not modified, regardless of the treatment sequence. There was no delayed renal toxicity. The study on the Krebs II ascites model confirms the tumor cell therapeutic potentiation without exacerbation of normal tissue damage.
在体内模型（将克雷布斯II腹水癌移植到雌性瑞士小鼠体内）上评估了不同放化疗组合的疗效、急性和迟发性毒性。小鼠接受单次剂量2.5至10 Gy的全腹照射（WAI）。顺铂在WAI前或后12小时以0.5至4 mg/kg的剂量腹腔注射。顺铂剂量与小鼠寿命延长（ILS）之间存在关联。然而，WAI并未延长寿命。当在2.5 Gy WAI之前给予2 mg/kg的单次顺铂剂量时，ILS达到47%。相比之下，当治疗顺序颠倒时，ILS仅为37%。当WAI剂量水平增加到5 Gy时，ILS并未增加。在最后一次治疗后3天测定的空肠隐窝细胞数量，无论治疗顺序如何，均未改变。没有迟发性肾毒性。对克雷布斯II腹水模型的研究证实了肿瘤细胞治疗增效作用，而不会加重正常组织损伤。
